Serum fetuin-A in diabetic and nondiabetic hemodialysis patients

Background:Diabetes mellitus is a major public health,it is associated with diabetic kidney disease,early prediction will help to prevent its hazards efficiently.Objective:To explorate the effect and assess the role of fetuin-A in diabetic and nondiabetic patients on hemodialysis. Patients and Methods: This is a prospective case-control study that was performed at the Internal Medicine Department, Minia University Hospital during the period from June 2021 to February 2022. The study included a total of 45 subjects who were classified to 3 groups (n=15 per each); group (I) included healthy subjects (non-diabetic and not on hemodialysis) served as control group (Control group), group (II), included non-diabetic patients on hemodialysis (HD group) and group (III) included diabetic patients on hemodialysis (DM+HD group). Serum Fetuin-A was measured by ELISA before and after hemodialysis. Results: There were significant differences among the three studied groups in Fetuin-A level (the highest level was in DM+HD group followed by HD group however the lowest level was noticed in the control group, p< 0.01). Also, DM patients group (group II and group III) had significantly higher Fetuin-A level compared to the control group (p< 0.01). There were significant differences between Group II and III in Fetuin-A before dialysis and the same trend of results was found after dialysis.Also, the higher Fetuin-A levels were associated with HTN and cardiac affected cases.Conclusion: Fetuin-A was significantly higher in diabetic patients on hemodialysis compared to non-diabetic patients on hemodialysis and the normal healthy subjectsKEYWORDS: Fetuin-A, Diabetes mellitus, Hemodialysis.